"Competition?  I know that some forum writers have said that SGLT2 inhibitors are competition for Apabetalone.  I don't see it that way. Our drug has had zero side effects.  SGLT2?  How about kidney failure, "increase in genital infections, particularly in women"?  For me, Apabetalone will easily take over the market from Jardiance as soon as it is approved. "

Apabetalone is not in the clear yet from a safety standpoint. SGLT2 inhibitors have gone through years and years of trials, including some long cardiovascular outcomes trials. Apabetalone still has yet to complete a trial longer than 6 months. The full safety data and adverse event profile from the BETonMACE trial will be very informative.

BearDownAZ